A pilot study for a randomized controlled and patient preference trial of buprenorphine versus methadone maintenance treatment in the management of opiate dependent patients

Pinto, Hayley; Rumball, Daphne; Maskrey, Vivienne; Holland, Richard

doi:10.1080/14659890701538810

Cited by 12 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These factors contribute to difficulty recruiting to randomized controlled trials to the extent that their generalizability can be severely compromised. A local pilot study found that the number of eligible subjects prepared to accept randomization constituted less than 2% (Pinto, Rumball, Maskrey, & Holland, 2008). Randomization and effective blinding also (in theory) divorce the results from patients' expectations about the effectiveness, for them as individuals, of the two alternative treatments.…”

Section: Introductionmentioning

confidence: 98%

The SUMMIT Trial:

Pinto

Maskrey

Swift

et al. 2010

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

This prospective patient-preference study examined the effectiveness in practice of methadone versus buprenorphine maintenance treatment and the beliefs of subjects regarding these drugs. A total of 361 opiate-dependent individuals (89% of those eligible, presenting for treatment over 2 years at a drug service in England) received rapid titration then flexible dosing with methadone or buprenorphine; 227 patients chose methadone (63%) and 134 buprenorphine (37%). Participants choosing methadone had more severe substance abuse and psychiatric and physical problems but were more likely to remain in treatment. Survival analysis indicated those prescribed methadone were over twice as likely to be retained (hazard ratio for retention was 2.08 and 95% confidence interval [CI] = 1.49-2.94 for methadone vs. buprenorphine), However, those retained on buprenorphine were more likely to suppress illicit opiate use (odds ratio = 2.136, 95% CI = 1.509-3.027, p < .001) and achieve detoxification. Buprenorphine may also recruit more individuals to treatment because 28% of those choosing buprenorphine (10% of the total sample) stated they would not have accessed treatment with methadone.

show abstract

Section: Introductionmentioning

confidence: 98%

The SUMMIT Trial:

Pinto

Maskrey

Swift

et al. 2010

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…Buprenorphine is a partial μ opioid agonist that was approved in 2002 by the FDA as a pharmacotherapy agent for the treatment of opioid use disorder in the United States (Fiellin et al, 2001; Food and Drug Administration, 2002). Buprenorphine is considered to be safer than methadone and equally effective for maintenance treatment (Pinto et al, 2008; Amass et al, 2012; Salisbury et al, 2012; Hser et al, 2014). Treatment using buprenorphine was reported to have good retention rates, treatment adherence, and patient as well as provider satisfaction (Becker and Fiellin, 2006; Pinto et al, 2008; Strobbe et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

“…Buprenorphine is considered to be safer than methadone and equally effective for maintenance treatment (Pinto et al, 2008; Amass et al, 2012; Salisbury et al, 2012; Hser et al, 2014). Treatment using buprenorphine was reported to have good retention rates, treatment adherence, and patient as well as provider satisfaction (Becker and Fiellin, 2006; Pinto et al, 2008; Strobbe et al, 2011). Unlike methadone clinics, which are typically housed in stand-alone facilities, buprenorphine treatment programs are office-based.…”

Section: Introductionmentioning

confidence: 99%

Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis

Wang

Nickasch

Lander

et al. 2017

Journal of Addiction Medicine

View full text Add to dashboard Cite

Objectives To retrospectively review clinic records to assess the difference between face-to-face and telepsychiatry buprenorphine Medication-assisted treatment (MAT) programs for the treatment of opioid use disorder on three outcomes: additional substance use, average time to achieve 30 and 90 consecutive days of abstinence, and treatment retention rates at 90 and 365 days. Methods Medical records of patients (N=100) who were participating in telepsychiatry and in face-to-face group-based outpatient buprenorphine MAT programs were reviewed and assessed using descriptive statistical analysis. Results In comparison with the telepsychiatry MAT group, the face-to-face MAT group showed no significant difference in terms of additional substance use, time to 30 days (p=0.09) and 90 days of abstinence (p=0.22), or retention rates at 90 and 365 days (p = 0.99). Conclusions We did not find any significant statistical difference between telepsychiatry buprenorphine MAT intervention through videoconference and face-to-face MAT treatment in our Comprehensive Opioid Addiction Treatment (COAT) model for individuals diagnosed with Opioid Use Disorder in terms of additional substance use, average time to 30 and 90 days of abstinence, and treatment retention rates.

show abstract

“…Items are rated on a three-point Likert scale, where 0='stable', 1='may not be stable' and 2='unstable'. The CISS is widely used in the United Kingdom [7,8], in outpatient services [9], methadone and opiate maintenance treatments [10] and drug intervention programmes [11], to assess the problem severity of drug abusers and to appraise the effectiveness of their treatment.…”

Section: Introductionmentioning

confidence: 99%

Six-Month Outcomes for Patients Attending a Substance Abuse Clinic in Hong Kong: A Retrospective Study

Lau¹

2014

J Alcohol Drug Depend

View full text Add to dashboard Cite

The aim of this retrospective study was to demonstrate the effectiveness of the services offered in the two Substance Abuse Clinics (SACs) in the New Territories East Cluster (NTEC) of Hong Kong. The case notes of 99 patients were reviewed. The Christo Inventory for Substance-Misuse Services (CISS) at intake and six months later were recorded. The CISS total scores were 5.9 ± 2.6 and 4.4 ± 2.3 (t=6.345, p<0.001) at intake and at the six-month follow-up, respectively. The majority of the subjects (64.6%) showed improvement at the six-month followup. They demonstrated significant improvement in psychological status (t=0.5202, p<0.001), drug/alcohol use (t=4.589, p<0.001), general health (t=4.500, p<0.001), degree of criminal activity (t=2.803, p = 0.006) and high-risk behaviour (risky sexual behaviour and/or the use of injectable substances; t=2.755, p=0.007), whereas there was no statistically significant improvement in the areas of social functioning, occupation, working relationships, ongoing support and treatment adherence. The current services provided by the SACs are effective and lead to a better overall outcome, although further improvement is needed in relation to the specific areas of occupation, ongoing support and treatment adherence.

show abstract

A pilot study for a randomized controlled and patient preference trial of buprenorphine versus methadone maintenance treatment in the management of opiate dependent patients

Cited by 12 publications

References 18 publications

The SUMMIT Trial:

The SUMMIT Trial:

Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis

Six-Month Outcomes for Patients Attending a Substance Abuse Clinic in Hong Kong: A Retrospective Study

Contact Info

Product

Resources

About